Everolimus: a review of its use in renal and cardiac transplantation (Q36441466)

14 August 2017

1 reference

title

Everolimus: a review of its use in renal and cardiac transplantation (English)

1 reference

14 August 2017

Christopher Dunn

1

1 reference

PubMed ID

16597167

14 August 2017

Katherine F Croom

series ordinal

2

1 reference

14 August 2017

1 January 2006

1 reference

14 August 2017

1 reference

14 August 2017

66

1 reference

14 August 2017

4

1 reference

14 August 2017

547-570

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-200666040-00009

14 August 2017

0 references

cites work

Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era.

1 reference

12 December 2020

Blood concentrations of everolimus are markedly increased by ketoconazole

1 reference

12 December 2020

Coadministration of neoral and the novel rapamycin analog, SDZ RAD, to rat lung allograft recipients: potentiation of immunosuppressive efficacy and improvement of tolerability of staggered versus simultaneous treatment.

1 reference

12 December 2020

Prevention of small airway obliteration in a swine heterotopic lung allograft model.

1 reference

12 December 2020

Pharmacokinetic and pharmacodynamic assessments of HMG-CoA reductase inhibitors when coadministered with everolimus

1 reference

12 December 2020

SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo

1 reference

12 December 2020

Benefit-risk assessment of sirolimus in renal transplantation

1 reference

12 December 2020

Chronic rejection and late renal allograft dysfunction

1 reference

12 December 2020

Everolimus in de novo cardiac transplantation: pharmacokinetics, therapeutic range, and influence on cyclosporine exposure

1 reference

12 December 2020

Everolimus and reduced-exposure cyclosporine in de novo renal-transplant recipients: a three-year phase II, randomized, multicenter, open-label study

1 reference

12 December 2020

Everolimus versus azathioprine in maintenance lung transplant recipients: an international, randomized, double-blind clinical trial.

1 reference

12 December 2020

Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies

1 reference

12 December 2020

Influence of hepatic impairment on everolimus pharmacokinetics: implications for dose adjustment

1 reference

12 December 2020

Introducing everolimus (Certican) in organ transplantation: an overview of preclinical and early clinical developments

1 reference

12 December 2020

Economic evaluation of everolimus vs. azathioprine at one year after de novo heart transplantation

1 reference

12 December 2020

Pharmacokinetics of an Everolimus-Cyclosporine Immunosuppressive Regimen Over the First 6 Months After Kidney Transplantation

1 reference

12 December 2020

Differential effect of cyclosporine A and SDZ RAD on neointima formation of carotid allografts in apolipoprotein E-deficient mice

1 reference

12 December 2020

Longitudinal assessment of everolimus in de novo renal transplant recipients over the first post-transplant year: pharmacokinetics, exposure-response relationships, and influence on cyclosporine

1 reference

12 December 2020

Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients

1 reference

12 December 2020

Influence of everolimus on steady-state pharmacokinetics of cyclosporine in maintenance renal transplant patients

1 reference

12 December 2020

Economic evaluation of everolimus versus mycophenolate mofetil in combination with cyclosporine and prednisolone in de novo renal transplant recipients

1 reference

12 December 2020

The UNOS Renal Transplant Registry.

1 reference

12 December 2020

Worldwide thoracic organ transplantation: a report from the UNOS/ISHLT International Registry for Thoracic Organ Transplantation

1 reference

12 December 2020

Heart transplantation in the Netherlands; costs, effects and scenarios

1 reference

12 December 2020

Rapamycin for immunosuppression in organ allografting.

1 reference

12 December 2020

Effect of SDZ RAD on transplant arteriosclerosis in the rat aortic model

1 reference

12 December 2020

1 reference

12 December 2020

Population pharmacokinetics of everolimus in de novo renal transplant patients: impact of ethnicity and comedications

1 reference

12 December 2020

Influence of delayed initiation of cyclosporine on everolimus pharmacokinetics in de novo renal transplant patients

1 reference

12 December 2020

Long-term pharmacokinetics of the metabolites of everolimus and cyclosporine in renal transplant recipients

1 reference

12 December 2020

Pharmacokinetics and tolerability of 40-0-[2-hydroxyethyl]rapamycin in de novo liver transplant recipients

1 reference

12 December 2020

RAD in stable lung and heart/lung transplant recipients: safety, tolerability, pharmacokinetics, and impact of cystic fibrosis

1 reference

12 December 2020

Multicenter intravascular ultrasound validation study among heart transplant recipients: outcomes after five years.

1 reference

12 December 2020

A blinded, randomized clinical trial of mycophenolate mofetil for the prevention of acute rejection in cadaveric renal transplantation. The Tricontinental Mycophenolate Mofetil Renal Transplantation Study Group

1 reference

12 December 2020

Cardiac allograft vasculopathy after heart transplantation: risk factors and management

1 reference

12 December 2020

Combined immunosuppression with cyclosporine (neoral) and SDZ RAD in non-human primate lung transplantation: systematic pharmacokinetic-based trials to improve efficacy and tolerability.

1 reference

12 December 2020

SDZ RAD, a new rapamycin derivative: synergism with cyclosporine

1 reference

12 December 2020

A randomized active-controlled trial of mycophenolate mofetil in heart transplant recipients. Mycophenolate Mofetil Investigators.

1 reference

12 December 2020

Causes of renal allograft loss. Progress in the 1980s, challenges for the 1990s

1 reference

12 December 2020

Everolimus (certican) in heart transplantation: optimizing renal function through minimizing cyclosporine exposure

1 reference

12 December 2020

Effect of food on everolimus absorption: quantification in healthy subjects and a confirmatory screening in patients with renal transplants

1 reference

12 December 2020

Differential effects of everolimus and cyclosporine A on intimal alpha-actin-positive cell dynamics of carotid allografts in mice

1 reference

12 December 2020

Pharmacokinetics of SDZ RAD and cyclosporin including their metabolites in seven kidney graft patients after the first dose of SDZ RAD.

1 reference

12 December 2020

Effect of multiple-dose erythromycin on everolimus pharmacokinetics

1 reference

12 December 2020

Early clinical experience with a novel rapamycin derivative

1 reference

12 December 2020

Everolimus and mycophenolate mofetil are potent inhibitors of fibroblast proliferation after lung transplantation.

1 reference

12 December 2020

Effects of rapamycin analogue SDZ RAD on obliterative lesions in a porcine heterotopic bronchial allograft model

1 reference

12 December 2020

Differential influence of two cyclosporine formulations on everolimus pharmacokinetics: a clinically relevant pharmacokinetic interaction

1 reference

12 December 2020

Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study

1 reference

12 December 2020

Viral triggers of cardiac-allograft dysfunction

1 reference

12 December 2020

Novel therapies in transplantation

1 reference

12 December 2020

Everolimus: a proliferation signal inhibitor targeting primary causes of allograft dysfunction.

1 reference

12 December 2020

The role of therapeutic monitoring of everolimus in solid organ transplantation

1 reference

12 December 2020

Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients

1 reference

12 December 2020

Chronic renal allograft rejection: immunologic and nonimmunologic risk factors

1 reference

12 December 2020

Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group

1 reference

12 December 2020

Coadministration of the new macrolide immunosuppressant RAD and mycophenolate mofetil in experimental corneal transplantation

1 reference

12 December 2020

Cost-effectiveness analysis of transplantation

1 reference

12 December 2020

SDZ-RAD prevents manifestation of chronic rejection in rat renal allografts

1 reference

12 December 2020

Entry-into-human study with the novel immunosuppressant SDZ RAD in stable renal transplant recipients.

1 reference

12 December 2020

Socioeconomic aspects of heart transplantation

1 reference

12 December 2020

Chronic transplant rejection

1 reference

12 December 2020

Everolimus and basiliximab permit suppression by human CD4+CD25+ cells in vitro

1 reference

12 December 2020

Cyclosporin: an updated review of the pharmacokinetic properties, clinical efficacy and tolerability of a microemulsion-based formulation (neoral)1 in organ transplantation

1 reference

12 December 2020

A randomized trial of steroid avoidance in renal transplant patients treated with everolimus and cyclosporine.

1 reference

12 December 2020

Comparison of the in vitro metabolism of the macrolide immunosuppressants sirolimus and RAD.

1 reference

12 December 2020

Effect of rifampin on apparent clearance of everolimus

1 reference

12 December 2020

A phase I study of a 4-week course of SDZ-RAD (RAD) quiescent cyclosporine-prednisone-treated renal transplant recipients

1 reference

12 December 2020

Exposure-response relationships for everolimus in de novo kidney transplantation: defining a therapeutic range

1 reference

12 December 2020

Mycophenolate mofetil. A review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in renal transplantation

1 reference

12 December 2020

SDZ RAD inhibits cold ischemia-induced vascular remodeling

1 reference

12 December 2020

Chemical modification of rapamycin: the discovery of SDZ RAD.

1 reference

12 December 2020

Tolerability and steady-state pharmacokinetics of everolimus in maintenance renal transplant patients

1 reference

12 December 2020

Therapeutic drug monitoring for everolimus in heart transplant recipients based on exposure-effect modeling

1 reference

12 December 2020

Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs

1 reference

12 December 2020

Oral efficacy of the macrolide immunosuppressant SDZ RAD and of cyclosporine microemulsion in cynomolgus monkey kidney allotransplantation

1 reference

12 December 2020

The peripheral lymphocyte count predicts graft survival in DA to Lewis heterotopic heart transplantation treated with FTY720 and SDZ RAD

1 reference

12 December 2020

Prevention of transplant rejection: current treatment guidelines and future developments

1 reference

12 December 2020

Improving outcomes in heart transplantation: the potential of proliferation signal inhibitors

1 reference

12 December 2020

Clinical pharmacokinetics of everolimus

1 reference

12 December 2020

Therapeutic drug monitoring for everolimus in kidney transplantation using 12-month exposure, efficacy, and safety data

1 reference

12 December 2020

Tissue distribution and clinical monitoring of the novel macrolide immunosuppressant SDZ-RAD and its metabolites in monkey lung transplant recipients: interaction with cyclosporine

1 reference

12 December 2020

Everolimus for the prevention of allograft rejection and vasculopathy in cardiac-transplant recipients

1 reference

12 December 2020

Determinants of chronic renal allograft rejection in cyclosporine-treated recipients

1 reference

12 December 2020

The in vivo effect of rapamycin derivative SDZ RAD on lymphocyte proliferation.

1 reference

12 December 2020

Improved graft survival after renal transplantation in the United States, 1988 to 1996

1 reference

12 December 2020

10.2165/00003495-200666040-00009

Identifiers

DOI

1 reference

PubMed ID

16597167

Dimensions Publication ID

14 August 2017

0 references

1 reference

PubMed ID

16597167